Alnylam Pharma Inc Live Stock Price Today, Share Analysis and Chart

Name: Alnylam Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: Alnylam Pharmaceuticals Inc
Rating: 2.164291625
Author: Trendlyne DVM scores

Expensive Performer

about

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the m...

422.50 16.10 (3.96%)

105.23% Gain from 52W Low

1.4M

XNAS Volume

XNAS 07 Jan, 2026 4:19 PM (EST)

Medium Financial Strength

50.0 / 100

Expensive Valuation

22.8 / 100

Technically Neutral

50.3 / 100

Expensive Performer These stocks have medium quality and momentum.Their expensive valuations suggest caution View Similar Embed DVM

491

1Yr Price target upside is 16%

24 analysts

Alnylam Pharma Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Alnylam Pharma Inc Live Stock Price Today, Share Analysis and Chart

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the m...

105.23% Gain from 52W Low

SWOT Analysis

Alnylam Pharma Inc Live Price Chart